Terms: = Leukemia AND MEN1, ENSG00000133895, 4221
54 results:
1. The dose-response effect of time between emergency admission and inpatient care on mortality.
Castaño-Pérez S; Medina García JA; Cabrera de León A
Sci Rep; 2023 Dec; 13(1):22244. PubMed ID: 38097684
[TBL] [Abstract] [Full Text] [Related]
2. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract] [Full Text] [Related]
3. Dependency of B-Cell Acute Lymphoblastic leukemia and Multiple Myeloma Cell Lines on men1 Extends beyond men1-KMT2A Interaction.
Wolffhardt TM; Ketzer F; Telese S; Wirth T; Ushmorov A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003662
[TBL] [Abstract] [Full Text] [Related]
4. Clinically Defined Mutations in
Duan S; Sheriff S; Elvis-Offiah UB; Witten BL; Sawyer TW; Sundaresan S; Cierpicki T; Grembecka J; Merchant JL
Cancer Res Commun; 2023 Jul; 3(7):1318-1334. PubMed ID: 37492626
[TBL] [Abstract] [Full Text] [Related]
5. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for leukemia and Cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract] [Full Text] [Related]
6. men1 mutations mediate clinical resistance to menin inhibition.
Perner F; Stein EM; Wenge DV; Singh S; Kim J; Apazidis A; Rahnamoun H; Anand D; Marinaccio C; Hatton C; Wen Y; Stone RM; Schaller D; Mowla S; Xiao W; Gamlen HA; Stonestrom AJ; Persaud S; Ener E; Cutler JA; Doench JG; McGeehan GM; Volkamer A; Chodera JD; Nowak RP; Fischer ES; Levine RL; Armstrong SA; Cai SF
Nature; 2023 Mar; 615(7954):913-919. PubMed ID: 36922589
[TBL] [Abstract] [Full Text] [Related]
7. Multifunctional liposomal nanostructure-mediated siRNA/bortezomib co-delivery for SHARP1 knockdown in MLL-AF6 acute myeloid leukemia.
Mohammed SA; Ju Y
Biomater Adv; 2022 Mar; 134():112663. PubMed ID: 35577689
[TBL] [Abstract] [Full Text] [Related]
8. Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases.
Zeng C; Bastarache LA; Tao R; Venner E; Hebbring S; Andujar JD; Bland ST; Crosslin DR; Pratap S; Cooley A; Pacheco JA; Christensen KD; Perez E; Zawatsky CLB; Witkowski L; Zouk H; Weng C; Leppig KA; Sleiman PMA; Hakonarson H; Williams MS; Luo Y; Jarvik GP; Green RC; Chung WK; Gharavi AG; Lennon NJ; Rehm HL; Gibbs RA; Peterson JF; Roden DM; Wiesner GL; Denny JC
JAMA Oncol; 2022 Jun; 8(6):835-844. PubMed ID: 35446370
[TBL] [Abstract] [Full Text] [Related]
9. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
[TBL] [Abstract] [Full Text] [Related]
10. Menin Enhances Androgen Receptor-Independent Proliferation and Migration of Prostate Cancer Cells.
Kim T; Jeong K; Kim E; Yoon K; Choi J; Park JH; Kim JH; Kim HS; Youn HD; Cho EJ
Mol Cells; 2022 Apr; 45(4):202-215. PubMed ID: 35014621
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic implications of menin inhibition in acute leukemias.
Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
[TBL] [Abstract] [Full Text] [Related]
12. Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
Libbrecht C; Xie HM; Kingsley MC; Haladyna JN; Riedel SS; Alikarami F; Lenard A; McGeehan GM; Ernst P; Bernt KM
Leukemia; 2021 May; 35(5):1405-1417. PubMed ID: 33542482
[TBL] [Abstract] [Full Text] [Related]
13. A Box of Chemistry to Inhibit the men1 Tumor Suppressor Gene Promoting leukemia.
Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
[TBL] [Abstract] [Full Text] [Related]
14. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract] [Full Text] [Related]
15. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged leukemia.
Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
[TBL] [Abstract] [Full Text] [Related]
16. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
17. Menin Associates With the Mitotic Spindle and Is Important for Cell Division.
Sawicki MP; Gholkar AA; Torres JZ
Endocrinology; 2019 Aug; 160(8):1926-1936. PubMed ID: 31211356
[TBL] [Abstract] [Full Text] [Related]
18. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.
Keating AK; Langenhorst J; Wagner JE; Page KM; Veys P; Wynn RF; Stefanski H; Elfeky R; Giller R; Mitchell R; Milano F; O'Brien TA; Dahlberg A; Delaney C; Kurtzberg J; Verneris MR; Boelens JJ
Blood Adv; 2019 Apr; 3(7):1118-1128. PubMed ID: 30952678
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
[TBL] [Abstract] [Full Text] [Related]
20. How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
Steinhilber D; Marschalek R
Biochem Pharmacol; 2018 Jan; 147():183-190. PubMed ID: 28943239
[TBL] [Abstract] [Full Text] [Related]
[Next]
